Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoceranib and Trifluridine/Tipiracil in mCRC
NCT04073615Phase 1Terminated
- Sponsor
- Elevar Therapeutics
- Start
- Nov 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Rivoceranib in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Elevar Therapeutics. Primary endpoints: Dose-limiting Toxicity, Adverse Events up to 3 years and 2 more. Started Nov 2019; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04073615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073615.